Very odd. To my knowledge, STAG2 deletions or mutations don't respond any differently to most other primary or secondary AMLs. (In fact, usually a secondary A

Very odd. To my knowledge, STAG2 deletions or mutations don't respond any differently to most other primary or secondary AMLs. (In fact, usually a secondary AML is a worse diagnosis as it means they have progressed from something like MDS, which itself has a shitty prognosis). Something is not quite right here. One possibility is that Seishi Ogawa's group has figured out that something off-label can more effectively treat cohesin mutants and it is under review. But I'm not sure how Watson would have known about that. Interesting. Probably my reading is flawed, but this doesn't make sense.